Merck Receives 2018 ENERGY STAR Sustained Excellence Award

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that it has received an ENERGY STAR 2018 Partner of the Year – Sustained Excellence Award from the U.S. Environmental Protection Agency (EPA) for its continued leadership in energy management in both the pharmaceutical and industrial sectors, and superior contributions to ENERGY STAR.  Merck’s accomplishments will be recognized by the EPA and the U.S. Department of Energy at a ceremony in Washington, D.C. on April 20, 2018.

Merck has been an ENERGY STAR partner since 1995 and recognized by the EPA for 13 consecutive years, two times as Partner of the Year and now an 11th time for Sustained Excellence.

“Merck’s philosophy of being a responsible corporate citizen includes a strong commitment to environmental and energy sustainability,” said Don Watson, vice president, global workplace & enterprise services, Merck. “Our collaborative partnership with ENERGY STAR continues to support our efforts to reduce greenhouse gas emissions, reduce waste, and increase our use of renewable energy sources.  We are proud of the continued efforts and commitment of our employees who have helped the company achieve this honor 13 years in a row.”

The award recognizes one Merck manufacturing site that has achieved ENERGY STAR rankings in the top 25 percent of pharmaceutical plant energy performance nationwide: Las Piedras, Puerto Rico.

Also achieving certification this year were six office buildings in Cokesbury, Whitehouse Station, Kenilworth, and Branchburg, N.J., as well as West Point and Upper Gwynedd, Pa.

For more information about Merck’s ongoing environmental and energy conservation efforts, please visit www.merckresponsibility.com.

-------

About ENERGY STAR

ENERGY STAR^® is the simple choice for energy efficiency. For over 25 years, EPA’s ENERGY STAR program has been America’s resource for saving energy and protecting the environment. Join the millions already making a difference at energystar.gov. More background information about ENERGY STAR can be found at energystar.gov/about and energystar.gov/numbers.

Thousands of industrial, commercial, utility, state, and local organizations—including more than 40 percent of the Fortune 500®—rely on their partnership with the U.S. Environmental Protection Agency (EPA) to deliver cost-saving energy efficiency solutions. Together, since 1992, ENERGY STAR and its partners have helped save American families and businesses over $450 billion and over 3.5 trillion kilowatt-hours of electricity while also achieving broad emissions reductions—all through voluntary action.

About Merck

For more than a century, Merck, a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer’s disease and infectious diseases including HIV and Ebola. For more information, visit www.merck.com 

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s 2017 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).